Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis

Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis

Obeticholic acid (OCA) is approved for the treatment of patients with primary biliary cholangitis (PBC) who are partial responders or intolerant to ursodeoxycholic acid. Reports of serious liver injury have raised concerns about its safety in cirrhosis. We investigated the effects of treatment with...

Full description

Bibliographic Details
Main Authors: Binu V. John, Kaley Schwartz, Cynthia Levy, Bassam Dahman, Yangyang Deng, Paul Martin, Tamar H. Taddei, David E. Kaplan
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1720

Internet

https://doi.org/10.1002/hep4.1720

Similar Items